Olivier Rascol

Olivier Rascol, MD, PhD


Professor of Clinical Pharmacology Departments of Clinical Pharmacology and Neurosciences, Faculty of Medicine Purpan, University UPS of Toulouse III, France


Doctor Olivier Rascol is Professor of Clinical Pharmacology in Toulouse University Hospital since 1993. He obtained his MD in Neurology (Toulouse, 1985) and his PhD in Neurosciences (Paris, 1992). Dr Rascol is running the Toulouse Clinical Investigation Centre since 1994 and the Toulouse European Space Clinic since 1998. He is also running a Research Group on Motricity in the Research Unit INSERM U825 and is the coordinator of the French Reference Center for Multiple System Atrophy (Atypical Parkinsonism). Dr Rascol is the chair of the national network of the 56 French Clinical Investigation Centers since 2008 and the chair of the NS-Park Neurosciences Network of the French CIC since 2010. From 2011, Dr Rascol is now coordinating the National French Clinical Research Infrastructure Network F-CRIN.

As a neuropharmacologist, Dr Rascol’s main fields of interest are Parkinson’s disease and movement disorders, drug development for Parkinson’s disease and functional neuroimaging. Dr Rascol has been actively involved in the development of several marketed antiparkinsonian medications (ropinirole, rasagiline). He is currently running several research programs for disease progression and symptomatic management of PD (motor signs, dyskinesias and on-off problems, non-motor signs such as pain and sleep problems) with new dopaminergic (dopamine agonists, dopamine reuptake inhibitors, MAO-B inhibitors…) and non-dopaminergic (serotonergic, glutamatergic, alpha-adrenergic…) drugs in collaboration with several academic and industry research centres in the US and in Europe. He is acting in this field as an external advisor for French and European scientific organisations, patients’ associations, drug agencies and international pharmaceutical companies. He is at the board of the Evidence-Based Medicine MDS Task Force in charge of the continuous assessment of all antiparkinsonian treatments. He is involved in the process of editing French (HAS) and European (EFNS / MDS-ES) guidelines for the treatment of Parkinson’s disease. As the chair of the French CIC Network and of the National F-CRIN Clinical Research infrastructure, Dr Rascol has been deeply involved within the last few years in the management and organisation of clinical research in France.

Dr Rascol is member of several French and American neurological and pharmacological societies. He was the Secretary of the international Movement Disorders Society (2006-2009) and is a member of the WFN Research Committee on Parkinsonism and Related Disorders. Dr Rascol is elected chair of the European Section of the Movement disorders Society since 2011. Dr Rascol is working or has worked as associate-editor for the Journal Fundamental and Clinical Pharmacology and is or has been a member of the editorial board of Lancet Neurology, Neurology, the European Journal of Neurology, the Journal of Neural Transmission, Evidence Medicine.

Dr Rascol has published 350 articles in International Scientific journals (New England Journal of Medicine, Lancet, Lancet neurology, Annals of Neurology, Neurology, Archives of Neurology, Brain, Movement Disorders…). His H factor is 50. He has also been invited to give more than 250 lectures in various European, North and South American and Asian universities or national and international meetings.